Author: embeds

Pulmonary Embolism (PE)

1. Initial assessment

Consider PE in unexplained breathlessness, pleuritic chest pain, syncope, haemoptysis, tachycardia or hypoxia.

Assess ABCDE, observations and haemodynamic stability. Obtain ECG and CXR where appropriate; neither excludes PE.

Cardiac arrest, obstructive shock or persistent hypotension (SBP <90 mmHg or fall ≥40 mmHg for >15 minutes, not otherwise explained).

  • Immediate senior ED and critical care involvement.
  • Resuscitate, provide oxygen and avoid excessive IV fluids in RV failure.
  • Urgent CTPA if feasible; bedside echo if too unstable for transfer.
  • Consider IV unfractionated heparin and urgent reperfusion, including systemic thrombolysis.

Do not delay emergency treatment for Wells, PERC or D-dimer.


2. Stable patient – Diagnostic pathway

PERC – Very low clinical suspicion only

Use PERC only when clinical suspicion is low and an alternative diagnosis is feasible. (Pre-test probability must be <15%)

All eight must be negative:

PERC CriterionRequired finding
Age<50 years
Heart rate<100/min
SpO₂≥95% on room air
Unilateral leg swellingAbsent
HaemoptysisAbsent
Recent surgery or significant trauma requiring hospitalisationAbsent
Previous DVT/PEAbsent
Exogenous hormone useAbsent

All negative: PE may be excluded without further testing in an appropriately selected patient.

Any positive or ongoing suspicion: calculate Wells.

Two-level Wells score

Wells Clinical FeaturePoints
Clinical DVT signs (leg swelling and deep vein tenderness)3
Alternative diagnosis less likely than PE3
Heart rate >100/min1.5
Immobilisation >3 days or surgery within 4 weeks1.5
Previous DVT/PE1.5
Haemoptysis1
Active/recent malignancy (treatment within 6 months or palliative)1

Wells >4 – PE likely: CTPA. Do not use D-dimer to exclude PE. Give interim therapeutic anticoagulation if imaging cannot be performed immediately, unless contraindicated.

Wells ≤4 – PE unlikely: D-dimer using CHFT thresholds. If results cannot be obtained within 4 hours, offer interim therapeutic anticoagulation unless contraindicated.

D-dimer – DDU assay thresholds

AgeNegative if
<50 years<230 ng/L
≥50 years<5 × age in years (ng/L)

Examples: 50 years <250; 60 <300; 70 <350; 80 <400; 90 <450.

  • Below threshold: PE excluded in the appropriate clinical context.
  • At or above threshold: imaging required.

Use only the locally validated assay and reporting units.

Imaging: CTPA first line

  • If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.
    • Heparin 80unit/kg OR treatment dose Tinzaparin – (Give Prior to Urgent CTPA)
  • Consider V/Q imaging if CTPA is unsuitable (e.g. selected patients with severe renal impairment or contrast allergy).
  • Consider U/S if evident DVT

For stable patients requiring investigation, calculate sPESI to assess potential suitability for SDEC.

sPESI criterionPoints
Age >80 years1
History of cancer1
Chronic heart failure or lung disease1
Heart rate ≥110/min1
SBP <100 mmHg1
SpO₂ <90%1
  • sPESI = 0 → Consider SDEC ensure referred and treated (mSDEC will contact patient with a time to attend)
  • sPESI ≥1 → Senior review, ED investigation or admission will be considered
  • If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.

3. Risk Stritification

RiskFeaturesManagement
HighCardiac arrest, shock or persistent hypotensionCritical care, urgent reperfusion assessment
Intermediate-highStable BP, elevated clinical risk (PESI III–V or sPESI ≥1), RV dysfunction and positive troponinMonitored admission, anticoagulation, senior/critical care review
Intermediate-lowStable BP, increased clinical risk and/or RV injury markers without meeting intermediate-high criteriaAnticoagulation, reassessment and appropriate monitoring
LowStable, usually sPESI 0, no concerning RV injury markersConsider SDEC/ambulatory treatment

4. Confirmed PE – Treatment

Low/Intermediate Risk – Anticoagulation

  • Apixaban or rivaroxaban first-line for most suitable patients.
  • Alternative anticoagulation may be needed in pregnancy, severe renal impairment, contraindications or selected cancer-associated VTE.
  • Check FBC, renal function, LFTs and coagulation screen; do not delay necessary treatment solely while awaiting results.
  • Treat confirmed PE for at least 3 months, then reassess duration.

High Risk – Thrombolysis decision

High-risk PE with a pulse

Actilyse (alteplase) – UK licensed regimen

WeightIV bolusIV infusionTotal
≥65 kg10 mg over 1–2 min90 mg over 2 h100 mg
<65 kg10 mg over 1–2 minRemainder over 2 hMaximum 1.5 mg/kg

Example: 60 kg → 10 mg bolus + 80 mg infusion = 90 mg total.

PE-related cardiac arrest

  • Consider fibrinolysis when PE is the suspected or confirmed cause of arrest.
  • Alteplase 50 mg IV bolus a further 50 mg may be considered.
  • Consider continuing CPR for 60–90 minutes after thrombolysis in selected patients.
  • Consider ECPR or alternative reperfusion where available.

Contraindications and monitoring

Check for major bleeding risk, including active bleeding, previous intracranial haemorrhage, recent stroke, intracranial pathology, recent major surgery or trauma, and recent anticoagulant use.

  • Monitor haemodynamics, bleeding and neurological status.
  • Follow local guidance for UFH interruption/resumption. The Actilyse SmPC advises starting or resuming heparin when aPTT is less than twice the upper limit of normal.
  • Discuss catheter-directed or surgical reperfusion if thrombolysis is contraindicated or unsuccessful.

5. Special circumstances and disposition

  • Pregnancy: use a pregnancy-specific PE pathway; LMWH is generally preferred.
  • Renal impairment/contrast allergy: discuss alternative imaging and anticoagulation with radiology/specialists.
  • Negative CTPA with persistent suspicion: reassess and discuss further investigation.

Consider admission for haemodynamic instability, significant oxygen requirement, RV dysfunction/myocardial injury requiring monitoring, significant comorbidity or unsafe ambulatory management.

For SDEC discharge: ensure anticoagulation supply, written bleeding/VTE advice, safety-netting and appropriate follow-up.


References

Hypothermia

Remove COLD, Add WARM, Don’t SHAKE

  • 32-35ºC [Mild] – Shivering, Tachycardia, Tachypnoeic, Vasoconstriction
  • 30-32ºC [Moderate] – Shivering stops, Pale/Cyanosed, Hypotensive, Confused, Lethargic
  • <30ºC [Severe] – Low GCS, Bradycardia/pnoeic, Hypotensive, Arrhythmias, Cardiac Arrest

Read more

Hypothermic Arrest [Adult]

True Hypothermic Arrest is thankfully rare in the UK. However, when it does happen it is resource intense and prolonged. The ERC 2025 guidance algorithms are below (both quick referance and detailed)

If the is HOPE score is <0.1  the team may which to consider terminating CPR [Warning: Adults ONLY Children have better survival] Read more

STEMI and Hyperkalaemia

Hyperkalaemia can mimic STEMI, but true coronary occlusion and hyperkalaemia may coexist. The challenge is to recognise the ECG abnormalities, confirm potassium rapidly, treat life-threatening hyperkalaemia and avoid delaying reperfusion.

The key principle is parallel management: investigate and treat hyperkalaemia while activating the primary PCI pathway when acute coronary occlusion remains a credible diagnosis.

Read more

Upper Gastrointestinal Bleed (UGIB)

Not normally difficult to spot, but look for it in unexplained anaemia, or collapse.

Questions

  • Is it VARICEAL? Mortality 35%, so is an emergency whatever the GBS is.
  • Non-Variceal what’s the GBS? will help guide treatment

Anyone being admitted should be brought to HRI

Emergency Endoscopy is arranged by Med Reg

Read more

Rabies [notifiable disease]

Recent Incident: Bat contact was not recognised (effectively touching a bat without gloves means treatment is recommended)

Important: Rabies Vaccine is in short supply and we must do a UKHSA risk assessment.  Call RIgS 09:30-17:00 7 days, Info required HERE

 

Rabies is an acute viral encephalomyelitis caused by members of the lyssavirus genus. The UK has been declared “Rabies-Free”. However, it is known that even in  “Rabies-Free” counties the bat population posse a risk.

The UK is free from classical rabies in terrestrial animals, but European bat lyssaviruses occur in UK bats, including Daubenton’s and serotine bats. All bat species should be considered potential rabies risks. Any bite, scratch or potentially significant direct contact requires prompt assessment using current UKHSA guidance, irrespective of the bat species. Despite our “low-risk” status in 2002 a man died from rabies caught in the UK from bat exposure.

Although rabies is rare it is fatal so we must treat appropriately, Public Health England – Green book details this.

Risk Assessment

To establish patients risk and thus treatment you need to establish the Exposure Category and Country Risk [Link to Country Risk]

Exposure Category

Combined Country/Animal & Exposure Risk

Treatment

Obviously patients with wounds will need appropriate wound care and cleaning, specifics for rabies are below.

If in ANY doubt, or you feel you need advice about treatment contact: On-Call Microbiologist (who will contact PHE or Virology advice)

 

You will likely need to liaise with the duty pharmacist to obtain vaccine or HRIG – which may need to be sent from a different hospital. [it is probably worth trying to obtain the 1st weeks treatment if possible, to avoid treatment delays]

IN HOURS 08:30AM-5PM PLEASE CALL PHARMACY TO INFORM THEM TO EXPECT A DELIVERY OF IMMUNOGLOBULIN SO THIS CAN BE SEGREGATED FOR THE CORRECT PATIENT. PLEASE ASK TO SPEAK TO THE RESPONSIBLE PHARMACIST                      CRH (4218/4279) HRI (2422/7123) 


UKHSA Rabies and Immunoglobulin Service (RIgS)

  • Telephone: 0330 128 1020

Routine operating hours: 09:30–17:00, seven days per week, including weekends.

All patients presenting with a possible rabies exposure should undergo an initial clinical assessment, including wound management, assessment of the exposure and previous vaccination history.

During routine hours: Contact RIgS for specialist risk assessment, advice on post-exposure vaccination and any requirement for human rabies immunoglobulin (HRIG).

Outside routine hours:

  • For the highest-risk exposures in patients who have not received their first post-exposure vaccine dose, contact the UKHSA emergency duty doctor service. These include head or neck exposures (excluding UK bat exposures under this specific criterion) and exposure to an animal confirmed to have rabies.
  • For other potential rabies exposures, administer a dose of rabies vaccine if the patient has not yet received vaccine, or if a scheduled dose is due, provided vaccine is available locally.
  • Contact RIgS after 09:30 the following day to complete the risk assessment and confirm further treatment.

All advice and administered treatment must be documented in the patient’s clinical record. Pharmacy must be informed of vaccine and HRIG administration, and arrangements made for subsequent doses.

HRIG: Indications, dosage and administration must follow the current UKHSA interim recommendations for HRIG use (June 2025), alongside the national rabies post-exposure treatment guidance.

Information required for next morning referral – HERE

 

Mitochondrial Disease

Mitochondrial diseases are a diverse group of inherited disorders characterised by dysfunction of the mitochondrial respiratory chain, resulting in impaired cellular energy production.

These conditions frequently affect multiple organ systems and can present significant challenges in the Emergency Department. Evidence to guide management remains limited, particularly for specific complications, and specialist advice is often required.

Key principles for emergency care:

Mitochondrial Disease Information

Access specialist NHS information about mitochondrial diseases, including clinical features, diagnosis and management.

View NHS Mitochondrial Disease Info

Clinical Care Guidelines

Access specialist NHS guidance for healthcare professionals on the assessment, management and ongoing care of patients with mitochondrial disease.

View NHS Clinical Care Guidelines

Hyperkalaemia

Remember: is it a haemolysed blood sample? (you can do an iSTAT)

Severity

  • Mild: 5.5-5.9mmol/l – No urgent action required (Dietary & Medication modification & GP F/U)
  • Moderate: 6.0-6.4mmol/l – Follow treatment guide (maybe suitable for discharge)
  • Severe: ≥6.5mmol/l OR ECG changes – Follow treatment guide, must admit

Read more